TSTD3 Inhibitors
The chemical class of TSTD3 inhibitors comprises a diverse range of compounds that target key signaling pathways involved in cellular proliferation, survival, and differentiation. One significant group of inhibitors includes those targeting the phosphoinositide 3-kinase (PI3K) pathway. Compounds such as Wortmannin, LY294002, and BKM120 inhibit PI3K activity, disrupting downstream signaling cascades mediated by Akt and mTOR. Inhibition of these pathways can indirectly suppress TSTD3 expression, as TSTD3 may be regulated by downstream effectors of PI3K signaling.
Another class of inhibitors targets the mitogen-activated protein kinase (MAPK) signaling pathway. Compounds like U0126, SB203580, and PD98059 inhibit MEK, a kinase upstream of ERK1/2 in the MAPK pathway. By blocking MEK activity, these inhibitors interfere with the activation of downstream signaling pathways, ultimately leading to the suppression of TSTD3 expression. Additionally, inhibitors such as Sorafenib, Gefitinib, and Trametinib target specific kinases within the RAF/MEK/ERK pathway, further contributing to the indirect inhibition of TSTD3.
Overall, the chemical class of TSTD3 inhibitors acts by modulating key signaling pathways involved in cancer development and progression. By targeting these pathways, these inhibitors can effectively suppress TSTD3 expression, highlighting their ability as agents for diseases associated with TSTD3 dysregulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a fungal metabolite that inhibits PI3K by irreversibly binding to its catalytic subunit. Inhibition of the PI3K pathway can indirectly inhibit TSTD3 by disrupting downstream signaling cascades. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a synthetic compound that selectively inhibits PI3K by competing with ATP for binding to the enzyme's catalytic site. By blocking PI3K activity, LY294002 can indirectly inhibit TSTD3 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a downstream effector of PI3K/Akt signaling pathway. Inhibition of mTOR can indirectly suppress TSTD3 expression by interfering with the activation of downstream signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a potent and selective inhibitor of MEK1 and MEK2, which are kinases involved in the MAPK/ERK signaling pathway. By blocking MEK activity, U0126 can indirectly inhibit TSTD3 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole compound that selectively inhibits p38 MAPK, a key component of the MAPK signaling pathway. Inhibition of p38 MAPK can indirectly suppress TSTD3 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK1 and MEK2, which are upstream kinases in the MAPK/ERK signaling pathway. By blocking MEK activity, PD98059 can indirectly inhibit TSTD3 expression. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
BKM120 is a potent and selective inhibitor of PI3K, targeting both the alpha and beta isoforms of the enzyme. Inhibition of PI3K by BKM120 can indirectly suppress TSTD3 expression by disrupting downstream signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple kinases involved in the RAF/MEK/ERK signaling pathway, including RAF, VEGFR, and PDGFR. By blocking this pathway, Sorafenib can indirectly inhibit TSTD3 expression. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is a selective inhibitor of the epidermal growth factor receptor (EGFR), which is upstream of the PI3K/Akt and MAPK/ERK signaling pathways. Inhibition of EGFR can indirectly suppress TSTD3 expression. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a highly selective inhibitor of MEK1 and MEK2, key components of the MAPK/ERK signaling pathway. Inhibition of MEK by Trametinib can indirectly suppress TSTD3 expression. | ||||||